Loading...
Loading...
COYA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 6.8K |
| Gross Profit | -6.8K |
| Operating Expense | 4,450.0K |
| Operating I/L | -4,450.0K |
| Other Income/Expense | 428.9K |
| Interest Income | 0.0K |
| Pretax | -4,021.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,021.0K |
Coya Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing proprietary medicinal products to modulate the function of regulatory T cells (Tregs). Their product candidate pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. They have completed Phase 2a clinical trial for COYA 101, an autologous regulatory T-cell product candidate for Amyotrophic Lateral Sclerosis. Additionally, they are developing Treg-enhancing biologics for Frontotemporal Dementia and a biologic combination for neurodegenerative and autoimmune diseases. Their focus on Treg-based therapies positions them at the forefront of developing treatments for neurodegenerative, autoimmune, and metabolic diseases.
